Medicare Formulary Review Should Avoid Comparisons To Medicaid Lists, AMCP Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Academy of Managed Care Pharmacy's comments on CMS' formulary review guidelines say some Medicaid preferred drug lists are based on cost, rather than medical appropriateness. Using cost-based PDLs as benchmarks will undermine evidence-based formularies, the group says.